switched from 10mg to 15mg and nausea got better, not worse
switched from 10mg to 15mg and nausea got better, not worse, which sounds obvious until you try to state the evidence for it. Numbers, in the order they matter: 10mg and 15mg. Sent a vial to VendorInvestigate out of curiosity. Result was 98.5% against a claimed 98.0%, which is the first independent number I had seen…
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
Left up. It reads the phase 2 paper carefully and it is honest about the intervals.
What is the source for that figure — the published paper or a summary of it?
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
research-use-only material is not approved for human use, full stop